<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01382810</url>
  </required_header>
  <id_info>
    <org_study_id>Altaire2011</org_study_id>
    <nct_id>NCT01382810</nct_id>
  </id_info>
  <brief_title>Altaire Gel Forming Solution Versus Refresh Tears for the Treatment of Dry Eye Signs and Symptoms</brief_title>
  <official_title>A Randomized Masked Evaluation of Altaire Gel Forming Solution Versus Refresh Tears for the Treatment of Dry Eye Signs and Symptoms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innovative Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Innovative Medical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate and compare the effects of Altaire Gel forming
      solution and Refresh Tears in mild-moderate dry eye patients.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2011</start_date>
  <completion_date type="Anticipated">October 2012</completion_date>
  <primary_completion_date type="Anticipated">October 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>TBUT</measure>
    <time_frame>2 months</time_frame>
    <description>Test performed that measures how long the tears take to break up</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Conjunctival and Corneal staining</measure>
    <time_frame>2 months</time_frame>
    <description>Dye that will be placed inside the eye to evaluate the surface of the ey</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Dry Eye Syndromes</condition>
  <arm_group>
    <arm_group_label>Altaire Gel forming solution</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Refresh Tears</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Altaire Gel forming solution</intervention_name>
    <description>Three times a day for two months</description>
    <arm_group_label>Altaire Gel forming solution</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Refresh Tears</intervention_name>
    <description>Three times a day for two months</description>
    <arm_group_label>Refresh Tears</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients 18 years or older.

          -  Males or females.

          -  Patient reported dry eye symptoms (episodic, annoying, activity limiting).

          -  Physician assessment of mild-moderate dry eye.

          -  Patient willing to instill drops TID and complete entire length of protocol.

          -  TBUT _&lt; 10 seconds.

          -  At least Grade 6 Corneal Staining.

        Exclusion Criteria:

          -  Current topical cyclosporine use (Restasis)

          -  Current Refresh use.

          -  Refractive surgery within the last 6 months.

          -  Oral or topical corticosteroid use.

          -  Severe dry eye patients by physician assessment.

          -  Current active blepharitis.

          -  Oral doxycycline use.

          -  Oral antihistamine use.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jenna Piel</last_name>
    <phone>951-653-5566</phone>
    <email>j.piel@imedsonline.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Jackson Eye, SC</name>
      <address>
        <city>Lake Villa</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annie Christensen</last_name>
      <phone>951-653-5566</phone>
      <email>a.christensen@imedsonline.com</email>
    </contact>
    <investigator>
      <last_name>Mitch Jackson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Koch Eye Associates</name>
      <address>
        <city>Warwick</city>
        <state>Rhode Island</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annie Christensen</last_name>
      <phone>951-653-5566</phone>
      <email>a.christensen@imedsonline.com</email>
    </contact>
    <investigator>
      <last_name>Paul Koch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 24, 2011</study_first_submitted>
  <study_first_submitted_qc>June 24, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2011</study_first_posted>
  <last_update_submitted>June 13, 2012</last_update_submitted>
  <last_update_submitted_qc>June 13, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 14, 2012</last_update_posted>
  <responsible_party>
    <name_title>Melissa Earl</name_title>
    <organization>CRO</organization>
  </responsible_party>
  <keyword>dry eye signs and symptoms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Signs and Symptoms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

